Program Description
Hereditary angioedema (HAE) is characterized by recurrent swelling of the skin and submucosal tissues, most commonly affecting the extremities, face, gastrointestinal tract, and airway. The management of HAE is complex, as frequency and severity of attacks vary widely between individuals and even within the same person over time. Acute on-demand treatment and prophylactic therapy options have emerged as the mainstays of HAE management. While each is effective, there are practical, safety, and economic limitations that affect real‑world use and patient quality of life. Challenges include burdensome routes of administration, treatment delays, breakthrough attacks despite prophylaxis, adverse effects, and high direct and system costs. This program will review clinical data for expanded long-term prophylaxis options in the HAE treatment landscape and focus on distinct profiles regarding efficacy, safety, and administration methods to support individualized treatment strategies. These expanded treatment options have the potential to reallocate healthcare expenditure from acute interventions toward preventive care strategies while simultaneously improving disease management. This discussion will also incorporate real-world data for long-term prophylaxis agents in HAE to equip managed care professionals and pharmacists to improve clinical, quality-of-life, and economic outcomes while still supporting patient access to appropriate agents for HAE treatment and management.
Target audience: Managed care pharmacists
Type of activity: Application
Release date: April 30, 2026
Expiration date: April 30, 2027
Learner level: Foundational, Intermediate
Time to complete activity: 1.5 hour
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Investigate the multifaceted clinical and economic impact of hereditary angioedema (HAE), encompassing treatment expenditures, healthcare utilization patterns, and the downstream effects of current management approaches on patient outcomes.
- Distinguish among current and emerging prophylactic therapies by assessing their comparative efficacy, safety profiles, and routes of administration to inform personalized and cost-conscious treatment decisions.
- Interpret recent innovations in on-demand HAE therapies and examine how these agents contribute to reducing attack burden, improving quality of life, and decreasing healthcare resource use.
- Identify managed care strategies to ensure timely access to HAE treatments, fostering continuity of care, and advancing evidence-based, value-oriented management strategies.